Rapamycin in Advanced Cancers
The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of rapamycin in patients with advanced cancers.
Advanced Cancer
DRUG: Rapamycin
Dose level equivalent to recommended phase 2/3 dose of temsirolimus, 6 weeks|observed toxicities, 6 weeks|anti-tumor effect, 6 weeks
The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of rapamycin in patients with advanced cancers.